Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Ballow

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Clinical Drug Investigation|March 29, 2008
Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy VolunteersC H Ballow, G W Amsden, V S Highet, et al.
The Journal of Antimicrobial Chemotherapy|May 4, 1999
Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacyV S Highet, A Forrest, C H Ballow, et al.
Biochemical Pharmacology|January 15, 1984
Inhibition of mixed-function oxidation in perfused rat liver by fluoroacetate treatmentJ L Zhou, F C Kauffman, C H Ballow, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 10, 2003
Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe)A Bolmstrom, C H Ballow, A Qwarnstrom, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2000
Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult malesP F Smith, A Forrest, C H Ballow, et al.
Antimicrobial Agents and Chemotherapy|May 19, 2000
Absolute bioavailability and disposition of (-) and (+) 2'-deoxy- 3'-oxa-4'-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humansP F Smith, A Forrest, C H Ballow, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1997
Modeling the response of pneumonia to antimicrobial therapyJ M Hyatt, A B Luzier, A Forrest, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1993
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacinA Forrest, C H Ballow, D E Nix, et al.
Clinical Therapeutics|September 18, 2001
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patientsP F Smith, C H Ballow, B M Booker, et al.
Diagnostic Microbiology and Infectious Disease|June 23, 1998
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and CanadaR N Jones, C H Ballow, D J Biedenbach, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Clinical Drug Investigation|March 29, 2008
Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy VolunteersC H Ballow, G W Amsden, V S Highet, et al.
The Journal of Antimicrobial Chemotherapy|May 4, 1999
Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacyV S Highet, A Forrest, C H Ballow, et al.
Biochemical Pharmacology|January 15, 1984
Inhibition of mixed-function oxidation in perfused rat liver by fluoroacetate treatmentJ L Zhou, F C Kauffman, C H Ballow, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 10, 2003
Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe)A Bolmstrom, C H Ballow, A Qwarnstrom, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2000
Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult malesP F Smith, A Forrest, C H Ballow, et al.
Antimicrobial Agents and Chemotherapy|May 19, 2000
Absolute bioavailability and disposition of (-) and (+) 2'-deoxy- 3'-oxa-4'-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humansP F Smith, A Forrest, C H Ballow, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1997
Modeling the response of pneumonia to antimicrobial therapyJ M Hyatt, A B Luzier, A Forrest, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1993
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacinA Forrest, C H Ballow, D E Nix, et al.
Clinical Therapeutics|September 18, 2001
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patientsP F Smith, C H Ballow, B M Booker, et al.
Diagnostic Microbiology and Infectious Disease|June 23, 1998
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and CanadaR N Jones, C H Ballow, D J Biedenbach, et al.
Pageof 3